Metabolic profiles of montelukast sodium (singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile

Drug Metabolism and Disposition

Volumn 25, Issue 11, 1997, Pages 1282-1287

  Balani, S K ^a,b   Xu, X ^a   Pratha, V ^c   Koss, M A ^c   Amin, R D ^a   Dufresne, C ^b   Miller, R R ^a   Arison, B H ^a   Doss, G A ^a   Chiba, M ^a   Freeman, A ^a   Holland, S D ^a   Schwartz, J I ^a   Lasseter, K C ^a   Gertz, B J ^a   Isenberg, J I ^c   Rogers, J D ^a   Lin, J H ^a   Baillie, T A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; SULFOXIDE;

ADULT; ARTICLE; ASPIRATION BIOPSY; ASTHMA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; T TUBE;

ACETATES; ADULT; BILE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INTERLEUKIN-1; LEUKOTRIENE ANTAGONISTS; MALE; MASS SPECTROMETRY; MIDDLE AGED; QUINOLINES;

EID: 0030696488     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. B. Dahlen, P. Hedqvist, S. Hammarstrom, and B. Samuelsson: The leukotrienes are potent constrictors of human bronchi. Nature (Lond.) 288, 484-486 (1980).
2. M. Griffin, J. W. Weiss, A. G. Leitch, E. R. McFadden, E. J. Corey, K. F. Austen, and J. M. Drazen: Effect of leukotriene D on the airways in asthma. N. Engl. J. Med. 308, 436-439 (1983).
3. Zafirlukast for asthma. Med. Lett. Drugs Ther. 38, 111-112 (1996).
4. 4 in asthmatics. Pulm. Pharmacol. 4, 37-42 (1991).
5. 4 receptor antagonist. Can. J. Physiol. Pharmacol. 67, 17-28 (1989).
6. T. R. Jones, R. Zamboni, M. Belley, E. Champion, L. Charette, A. W. Ford-Hutchinson, J.-Y. Gauthier, S. Leger, A. Lord, P. Musson, C. S. McFarlane, K. M. Metters, C. Pickett, H. Piechuta, and R. N. Young: Pharmacology of leukotriene antagonist verlukast: the (R)-enantiomer of MK-571. Can. J. Physiol. Pharmacol. 69, 1847-1854 (1991).
7. H. Yamamoto, M. Nagata, K. Kuramitsu, K. Tabe, H. Kiuchi, Y. Sakamoto, K. Yamamoto, and Y. Dohi: Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am. J. Respir. Crit. Care Med. 150, 254-257 (1994).
8. I. Gorenne, J. L. Ortiz, C. Labat, T. Abram, S. Tudhop, N. Cuthbert, P. Norman, P. Gardiner, E. Morcillo, and C. Brink: Antagonism of leukotriene responses in human airways by BAY x7195. Eur. J. Pharmacol. 275, 207-212 (1995).
9. 4 receptor antagonist. Can. J. Physiol. Pharmacol. 73, 191-201 (1995).
10. M. C. Liu, L. M. Dube, and J. Lancaster: Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial: Zileuton Study Group. J. Allergy Clin. Immunol. 98, 859-871 (1996).
11. M. Labelle, M. Belley, Y. Gareau, J. Y. Gauthier, D. Guay, R. Gordon, S. G. Grossman, T. R. Jones, Y. Leblanc, M. McAuliffe, C. McFarlane, P. Masson, K. M. Metters, N. Ouimet, D. H. Patrick, H. Piechuta, C. Rochette, N. Sawyer, Y. B. Xiang, C. B. Pickett, A. W. Ford-Hutchinson, R. J. Zamboni, and R. N. Young: Discovery of MK0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg. Med. Chem. Lett. 5, 283-288 (1995).
12. I. Delepeleire, T. F. Reiss, F. Rochette, A. Botto, J. Zhang, S. Kundu, and M. Decramer: Montelukast causes prolonged, potent leukotriene D-4-receptor antagonism in the airways of patients with asthma. Clin. Pharmacol. Ther. 61, 83-92 (1997).
13. 4) antagonist (MK-0476) in patients with asthma. Am. J. Respir. Crit. Care Med. 149, A216 (1994).
14. T. F. Reiss, L. C. Altman, P. Chervinsky, A. Bewtra, W. E. Stricker, G. P. Noonan, S. Kundu, and J. Zhang: Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD-4) receptor antagonist, in patients with chronic asthma. J. Allergy Clin. Immunol. 98, 528-534 (1996).
15. H. Cheng, J. A. Leff, R. Amin, B. J. Gertz, M. DeSmet, N. Noonan, J. D. Rogers, W. Malbecq, D. Meisner, and G. Somers: Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm. Res. 13, 445-448 (1996).
16. D. L. Nahrwold: The biliary system. In "The Textbook of Surgery" (D. C. Sabiston, ed.), pp. 1128-1169. W. B. Saunders, Philadelphia, 1986.
17. J.-C. Delchier, P. Benfredj, A.-M. Preaux, J.-M. Metrcau, and D. Dhumeaux: The usefulness of microscopic bile examination in patients with suspected microlithiasis: a prospective evaluation. Hepatology 6, 118-122 (1986).
18. R. D. Amin, H. Cheng, and J. D. Rogers: Determination of MK-0476 in human plasma by liquid chromatography. Pharm. Biomed. Anal. 13, 155-158 (1995).
19. M. B. d'Yvoire, A. Coquerel, P. Chretien, and D. Tremblay: Pooling plasmas for a rapid answer in pharmacokinetic studies: application to a bioequivalence study of hydrocortisone tablets. Fundam. Clin. Pharmacol. 7, 253-260 (1993).
20. M. L. Rocci and W. J. Jusko: LAGRAN program for area and moments in pharmacokinetic analyses. Comput. Programs Biomed. 16, 203-216 (1983).
21. 4 antagonist. In "Proceedings of the 10th International Symposium on Microsomes and Drug Oxidations," p. 612, 1994.
22. C. Dufresne, M. Gallant, Y. Gareau, R. Ruel, L. Trimble, and M. Labelle: Synthesis of montelukast (MK-0476) metabolic oxidation products. J. Org. Chem. 61, 8518-8525 (1996).
23. B. S. Drasar and M. J. Hill: "Human Intestinal Flora," pp. 54-102, 159-168. Academic Press, New York, 1974.
24. P. R. Steinmetz and C. Balko: Therapeutic implications of the intestinal microflora. N. Engl. J. Med. 289, 623-628 (1973).
25. A. Wee, B. Nilsson, T. L. Wang, I. Yap, and P. Y. Siew: Tuberculous pseudotumor causing biliary obstruction: report of a case with diagnosis by fine needle aspiration biopsy and bile cytology. Acta Cytol. 39, 559-562 (1995).
26. S. H. Hussaini, C. Kennedy, S. P. Pereira, J. A. Wass, and R. H. Dowling: Ultrasound-guided percutaneous fine needle puncture of the gall bladder for studies of bile composition. Br. J. Radiol. 68, 271-276 (1995).
27. J. Niu, N. H. Shou, J. F. Forbes, X. Y. Sun, S. Y. Hu, and F. J. Liu: Laparoscopic exploration of intra-and extrahepatic bile ducts and T-tube drainage. Aust. N. Z. J. Surg. 65, 189-193 (1995).
28. H. Cheng, M. S. Schwartz, S. Vickers, J. D. Gilbert, R. D. Amin, B. Depuy, L. Liu, J. D. Rogers, S. M. Pond, C. A. Duncan, T. V. Olah, and W. F. Bayne: Metabolic disposition of simvastatin in patients with T-tube drainage. Drug Metab. Dispos. 22, 139-142 (1994).
29. J. F. Westphal, F. Jehl, M. Schloegel, H. Monteil, and J. M. Brogard: Biliary excretion of cefixime: assessment in patients provided with T-tube drainage. Antimicrob. Agents Chemother. 37, 1488-1491 (1993).
30. J. Tudyka, W. Kratzer, K. Kuhn, P. Janowitz, J. G. Wechsler, and G. Adler: Diagnostic value of fine-needle puncture of gall bladder: side effects, safety, and prognostic value. Hepatology 21, 1303-1307 (1995).
31. S. W. Hosking, C. N. Hacking, J. Herbetko, and K. C. Dewbury: Safety and feasibility of percutaneous ultrasound guided puncture of the gall-bladder for crystal analysis. J. Gastroenterol. Hepatol. 7, 379-381 (1992).
32. J. A. Williams, P. J. Treacy, P. Sidey, C. S. Worthley, N. C. Townsend, and E. A. Russell: Primary duct closure versus T-tube drainage following exploration of the common bile duct. Anst. N. Z. J. Surg. 64, 823-826 (1994).
33. C. G. Wilson and N. Washington: "Physiological Pharmaceutics. Biological Barriers to Drug Absorption." pp. 47-90. John Wiley & Sons, New York, 1989.
34. A Lanzini, R. P. Jazrawi, and T. C. Northfield: Simultaneous quantitative measurements of absolute gallbladder storage and emptying during fasting and eating in humans. Gastroenterology 92, 852-861 (1987).
35. J. H. Lin, M. Chiba, S. K. Balani, I.-W, Chen, G. Y.-S. Kwei, K. J. Vastag, and J. A. Nishime: Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24, 1111-1120 (1996).
36. 4 receptor antagonist, in humans. Drug Metab. Dispos. 25, 1022-1031 (1997).